Illumisoft and Capgemini Collaborate to Advance Human-Safe Far UVC Platform for Airborne Pathogen Risk Reduction in High-Occupancy Indoor Environments

Executive Summary

• Illumisoft Lighting Corp. has entered into a strategic product development engagement with Capgemini to accelerate the development and commercialization of its SaniLux 216nm far UVC disinfection platform.
• The partnership leverages Capgemini’s frog and Synapse divisions to advance the platform through industrial design, engineering architecture, manufacturing readiness, and commercialization planning.
• The engagement aims to transition SaniLux from a technology development stage to a scalable, manufacturable commercial product family for high-occupancy indoor environments.

Key Details

• Parties Involved: Illumisoft Lighting Corp. (TSXV: UVC) and Capgemini (specifically frog and Synapse divisions).
• Objective: To advance the SaniLux platform from its current technology development stage toward a designed, engineered, and manufacturable commercial product family.
• Scope of Work: The engagement covers market and technology assessment, supply chain and manufacturing review, industrial design, engineering architecture, form factor development, prototyping, minimum viable product planning, pilot readiness, third-party study support, and new product introduction planning.
• Target Applications: Healthcare facilities, long-term care settings, transportation hubs, hospitality venues, educational institutions, commercial real estate, and major entertainment venues.
• Technology Focus: SaniLux utilizes 216 nanometre far UVC light, which research suggests can inactivate airborne pathogens without the skin and eye hazards associated with conventional germicidal UV wavelengths, allowing for continuous use in occupied spaces.
• Financial Terms: The financial terms of the engagement are confidential and not material to the Company's financial position.
• Market Context: Management estimates the global market for ultraviolet disinfection technologies is in the multi-billion dollar range, growing at a double-digit compound annual rate.

Notable Quotes

• Ehsan Agahi, Executive Chair of Illumisoft: "SaniLux is being developed to address that problem by enabling a potential continuous use far UVC disinfection platform for occupied spaces. Our objective is to turn SaniLux from a promising technology platform into a scalable and safe commercial product family... Working with Capgemini supports our efforts to advance the platform toward commercialization by complementing our semiconductor and lighting expertise with product design, engineering, manufacturing readiness, and commercialization capabilities."
• Ryan Starling, Head of Industrial Design, West Coast, frog: "Far UVC has transformative potential for human health and well-being, aligning closely with frog's mission to better the human experience. We are proud to support Illumisoft in shaping and bringing this technology into the spaces where people live and work."
• Kaethe Henning, Director, Consumer HealthTech Business of Synapse: "We believe Illumisoft's far UVC technology represents an important scientific breakthrough. Together, we're focused on turning that innovation into a manufacturable, scalable, and reliable product that can deliver real-world impact."